Expression modes and clinical manifestations of latent membrane protein 1, Ki‐67, cyclin‐B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma

Taheri-Kadkhoda, Zahra; Magnusson, Bengt; Svensson, Marie; Mercke, Claes; Björk‐Eriksson, Thomas

doi:10.1002/hed.21002

Cited by 33 publications

(34 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further research is needed to evaluate EGFR expression to clinical outcome of NPC. In this large sample study, we found that advancedstage (III-IVa) NPC had a high level expression of EGFR, which was significantly correlated with T stages, clinical stages, local recurrence, and poor prognosis of the patients, and patients with over-expression of EGFR increased risk of locoregional failure and had a reduced survival compared to those patients without, which was in accordance with previous reports [28,29] in NPC and other malignancies [30]. The expression of EGFR intensified in cancer tissues proportional to the increase in tumor extent measured by TNM staging with a statistical significance, indicating that over-expression of EGFR may play some roles not only in NPC pathogenesis but also in NPC progression.…”

Section: Discussionsupporting

confidence: 93%

Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma

et al. 2011

View full text Add to dashboard Cite

The purpose of this study was to evaluate the prognostic value of expression of EGFR and nm23 in patients with advanced-stage nasopharyngeal carcinoma (NPC). The study population comprised 127 patients with stage III-IVa NPC with sufficient pretreatment tumor biopsy specimens from 2003 to 2004 and clinical follow-up data. The expression of EGFR and nm23 was detected by immunohistochemistry. Survival analysis was performed using Kaplan-Meier method. The correlation between pretreatment expression of EGFR and nm23, and the effectiveness of chemoradiotherapy was analyzed. The EGFR expression was correlated with primary lesion stage and clinical stage (P = 0.001, 0.002, respectively). There was a statistically significant association between nm23 expression and local lymph node stage (P = 0.000). The positive EGFR expression had a higher recurrent rate than the negative (P = 0.015). The positive nm23 expression had a lower distant metastasis rate than the negative (P = 0.021). Negative expression of EGFR had a significantly better 5-year OS and DFS than positive expression (P = 0.015, 0.013, respectively). Positive expression of nm23 had a significantly higher 5-year OS and DFS than negative expression (P = 0.001, 0.006, respectively). Multivariate analysis indicated that both pretreatment EGFR and nm23 expression were strong independent factors for the overall survival of patients with NPC (P = 0.000, 0.000, respectively). Our data suggested that EGFR and nm23 can serve as reliable biomarkers for prognosis prediction in patients with NPC who may benefit from alternate treatment strategy and targeted treatment.

show abstract

Section: Discussionsupporting

confidence: 93%

Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Finally, we enrolled 15 eligible articles containing survival outcomes [11,[15][16][17][18]22,[24][25][26][27][28][29][30][31][32][33][34][35], among which two studies were written in Chinese [22,33], whereas the others were English articles. These eligible studies were published from 2002 to 2012.…”

Section: Eligible Studiesmentioning

confidence: 99%

Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis

Huang

et al. 2014

CBM

View full text Add to dashboard Cite

show abstract

“…It has been proved to have significant benefit in clinical treatments for metastatic colorectal cancer, advanced head and neck cancer, and advanced non-small cell lung cancer [17][18][19]. In addition, recent studies have demonstrated that EGFR was overexpressed in .80% of NPC [20][21][22]. Therefore, it is important to investigate the feasibility of applying C225-conjugated USPIO in tumor-targeted imaging.…”

Section: Introductionmentioning

confidence: 99%

Specific targeting of nasopharyngeal carcinoma cell line CNE1 by C225-conjugated ultrasmall superparamagnetic iron oxide particles with magnetic resonance imaging

Liu

Chen

et al. 2011

ABBS

View full text Add to dashboard Cite

An accurate definition of clinical target volume (CTV) is essential for the application of radiotherapy in nasopharyngeal carcinoma (NPC) treatment. A novel epidermal growth factor receptor (EGFR)-targeting contrast agent (C225-USPIO) was designed by conjugating ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles with cetuximab (C225), to non-invasively define the CTV of tumor. The immunobinding activity of C225-USPIO to NPC cell line CNE1 was confirmed by flow cytometry and immunofluorescence. The time-dependent accumulation of C225-USPIO in CNE1 cells was evaluated using Prussian blue staining. Targeted internalization and subcellular localization of C225-USPIO was confirmed by transmission electron microscope. The results indicated that C225-USPIO specifically bound to EGFR on the surface of CNE1 cells and was taken up into the cell. The uptake of C225-USPIO by CNE1 cells increased significantly with time, when compared with human IgG-USPIO. In addition, 4.7 T magnetic resonance imaging (MRI) revealed that C225-USPIO had a capacity to accumulate in the CNE1 cells, with a resultant marked decrease in MRI T2-weighted signal intensity over time. These findings imply that C225-USPIO has the potential as an MRI contrast agent and can be employed to non-invasively detect early-stage NPC with EGFR overexpression. This provides sufficient theoretical basis for commencing in vivo experiments with the compound.

show abstract

Expression modes and clinical manifestations of latent membrane protein 1, Ki‐67, cyclin‐B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma

Abstract: Our results suggest that the evaluation of EGFR staining intensity in patients with NPC may identify a subgroup of patients with poor prognosis.

Cited by 33 publications

References 33 publications

Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma

Prognostic value of expression of EGFR and nm23 for locoregionally advanced nasopharyngeal carcinoma

Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis

Specific targeting of nasopharyngeal carcinoma cell line CNE1 by C225-conjugated ultrasmall superparamagnetic iron oxide particles with magnetic resonance imaging

Contact Info

Product

Resources

About